The Lancet Infectious Diseases

The Research in context panel from the Article presenting the primary trial results, providing background for the research, the added value of the study, and implications of all the available evidence

🆕 The PRUDENCE investigators report their multicounty RCT of a point-of-care testing strategy to aid antibiotic prescribing for respiratory tract infections, and the embedded qualitative process evaluation

Read the trial results bit.ly/4lgz0uy
Read the embedded process evaluation bit.ly/40c9SLM

🍃March issue out now!

New data on cardiac events in #COPD, septic shock, climate change and #TB, and much more

🔗 www.thelancet.com/issue/S2213-...

Read our March issue!

Featuring RSV vaccination in elderly people, itraconazole for pulmonary aspergillosis and the global burden of Chagas disease.

bit.ly/3N5mqBx

ETVAX Phase 2b Trial Conducted in The Gambia Published in The Lancet Infectious ETVAX Phase 2b Trial Conducted in The Gambia Published in The Lancet Infectious Diseases, Marking a Major Milestone for Global Diarrhoeal Disease Prevention | LSHTM

#PublicationAlert 🚨

A new study published by @thelancetinfdis.bsky.social, in partnership with Scandinavian Biopharma, shows that the ETVAX vaccine can significantly reduce severe diarrhoea in young children.

Read more: tinyurl.com/yc7m34wx

#GlobalHealth #ChildHealth #VaccinesWork

Development and validation of the AURIS score for predicting candidaemia in Candidozyma auris-colonised patients in the intensive care unit: a bicentric retrospective cohort study The AURIS score provides a pragmatic tool for risk stratification among C auris-colonised ICU patients, with value in identifying those at low risk of candidaemia, reducing unnecessary empirical antif...

New Research

Development and validation of the AURIS score for predicting candidaemia in Candidozyma auris-colonised patients in the intensive care unit: a bicentric retrospective cohort study

www.thelancet.com/journals/lan...

The Lancet Global Health editors on conferences, implementation, and 2026 Podcast Episode · The Lancet Global Health in conversation with · 02/16/2026 · 29m

🎙️ Our podcast this month features your TLGH editorial team! Zoë, Pingyue, Gavin, and Shangrong discuss the problems with conferences in HICs, equitable research partnership, and the research we'd like to see in 2026!
Apple: podcasts.apple.com/us/podcast/t...
Spotify: open.spotify.com/episode/2y7y...

Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial ETVAX was safe and immunogenic. Although the primary endpoint was not met, the secondary and exploratory findings suggest ETVAX protects Gambian children against ETEC-positive MSD particularly when ad...

New Research

Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial

www.thelancet.com/journals/lan...

The looming crisis of bedaquiline-resistant tuberculosis and a promising way forward Drug-resistant tuberculosis is entering a new and dangerous phase. Bedaquiline and other newer drugs have transformed drug-resistant tuberculosis treatment, yet resistance to these agents is now being...

New Personal View

The looming crisis of bedaquiline-resistant tuberculosis and a promising way forward

www.thelancet.com/journals/lan...

I worked at WHO: the USA leaving will not make America healthier On Jan 30, 2020, WHO declared COVID-19 a Public Health Emergency of International Concern (PHEIC), the highest alarm it can sound, which is used for moments when the world must act together or risk ca...

New comment

I worked at WHO: the USA leaving will not make America healthier

www.thelancet.com/journals/lan...

A newborn baby being examined at the Simao Mendez central hospital in Bissau. Copyright: Giacomo Pirozzi/Panos Pictures.

"...randomly assigning newborns to not receive the vaccine denies a safe and life-saving intervention to infants in Guinea-Bissau."

New World Report by Gilbert Nakweya ⤵️ spkl.io/63325AsFTL

Reimagining radical cure for Plasmodium vivax Eliminating Plasmodium vivax malaria remains one of the most persistent challenges in global health. Relapses from dormant liver-stage hypnozoites continue to be the major biological barrier to contro...

New comment

Reimagining radical cure for Plasmodium vivax

www.thelancet.com/journals/lan...

Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, rand... Both unsupervised 7-day high-dose primaquine and single-dose tafenoquine were well tolerated in patients with normal G6PD activity and they had a lower risk of P vivax recurrence compared with those i...

New Research

Effectiveness and safety of 7-day high-dose primaquine and single-dose tafenoquine versus 14-day low-dose primaquine in patients with Plasmodium vivax malaria (EFFORT): a multicentre, open-label, randomised, controlled, superiority trial

www.thelancet.com/journals/lan...

Time to re-evaluate combination antifungal therapy for invasive aspergillosis and other invasive mycoses Mortality from invasive aspergillosis remains unacceptably high, and the currently recommended treatment of triazoles is further challenged by rising resistance to these first-line agents. A previous ...

New Personal View

Time to re-evaluate combination antifungal therapy for invasive aspergillosis and other invasive mycoses

www.thelancet.com/journals/lan...

Circulation of clade Ib mpox outside of Africa—are we prepared? Mpox is a spectrum of disease caused by monkeypox virus, which is divided into clades I (with subclades Ia and Ib) and II (with subclades IIa and IIb).1 In 2022, simultaneous detection of non-travel-a...

New comment

Circulation of clade Ib mpox outside of Africa—are we prepared?

www.thelancet.com/journals/lan...

Call for letters With the start of 2026, we are looking back at what we achieved last year and ahead to the coming year. One highlight of the coming year includes the 25-year anniversary of our first issue being publi...

New Editorial

Call for letters

www.thelancet.com/journals/lan...

Strength of ATLAS or lady luck in a sepsis management trial? In untreated people with HIV in sub-Saharan Africa, tuberculosis is the leading cause of mortality and sepsis,1 and accounts for 25–30% of bloodstream infections.2 Although a retrospective study found...

New comment

Strength of ATLAS or lady luck in a sepsis management trial?

www.thelancet.com/journals/lan...

Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial Among all participants with HIV-related sepsis, 28-day mortality was not significantly reduced with immediate or high-dose antituberculosis therapy. In the subgroup with later confirmed tuberculosis, ...

New Research

Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial

www.thelancet.com/journals/lan...

Read our February issue!

Featuring long COVID after reinfection in children and adolescents, testing the MAM01 monoclonal antibody for malaria, and household transmission dynamics of mpox in Burundi.

www.thelancet.com/issue/S1473-...

Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial Vi-CRM197+O:2-CRM197 formulations did not raise safety concerns and showed immunogenicity with a single dose, supporting further clinical assessment of the full-dose without aluminium hydroxide in tar...

New Research

Safety and immunogenicity of a conjugate vaccine candidate against Salmonella enterica serovars Typhi and Paratyphi A in healthy adults in Europe: a phase 1 randomised controlled trial

www.thelancet.com/journals/lan...

New research article

Emerging terbinafine-resistant #Trichophyton indotineae between 2018 and 2023: a multinational genomic epidemiology study

www.thelancet.com/journals/lan...

#IDSky #ClinMicro #MycoSky #AMR #OpenAccess #OA

Leprosy Leprosy, also known as Hansen's disease, is a curable granulomatous condition caused by Mycobacterium leprae or Mycobacterium lepromatosis, disproportionately affecting impoverished communities across...

Excited to announce our new Seminar on Leprosy just published online in @TheLancet! 🌍

This multicontinental collaboration provides an update on key public health & clinical aspects of leprosy

@thelancet.com @cudeptofmedicine.bsky.social @cudivofid.bsky.social

www.thelancet.com/journals/lan...

Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study Both doses of CRS3123 were deemed safe and well tolerated and showed efficacy similar to vancomycin at the TOC visit, with lower rates of recurrence. Together, these data support further development o...

New Research

Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study

www.thelancet.com/journals/lan...

January cover of The Lancet Microbe

Our January issue is now online:

www.thelancet.com/journals/lan...

Our journal is #OpenAccess, so you are free to explore all of our content. But these hashtags offer a flavour: #influenza #H5N1 #AMR #Bordetella #pertussis #Yaws #Treponema #MDA #Hpylori #SARS-CoV-2

#IDSky #ClinMicro #OA

Nirsevimab over two RSV seasons: do the findings align with expectations? The implementation of early respiratory syncytial virus (RSV) infection prevention with the long-acting monoclonal antibody nirsevimab during the 2023–24 cold season marked a major turning point for i...

New comment
Nirsevimab over two RSV seasons: do the findings align with expectations?

www.thelancet.com/journals/lan...

Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective... Universal infant nirsevimab prophylaxis markedly reduced RSV-related hospitalisations and outpatient morbidity, with sustained reductions in RSV-related LRTI hospitalisations into the second season an...

New Research

Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): a population-based prospective observational study

www.thelancet.com/journals/lan...

The effectiveness of long-lasting spatial repellent emanators against malaria in humanitarian crisis settings in northern Nigeria: a two-arm pragmatic, open-label, controlled trial These findings contribute to expanding the toolbox of efficacious vector control products for the humanitarian emergency context, strengthening the growing evidence for the public health value of spat...

New Research

The effectiveness of long-lasting spatial repellent emanators against malaria in humanitarian crisis settings in northern Nigeria: a two-arm pragmatic, open-label, controlled trial

www.thelancet.com/journals/lan...

Amber Barton on mass drug administration to eradicate yaws in Papua New Guinea - The Lancet Microbe in conversation with Phoebe Ashley-Norman of The Lancet Microbe speaks to Amber Barton about the neglected tropical disease, yaws. Efforts to eradicate yaws were first made in the 1950s through a WHO and UNICEF campaign t...

Also, author Amber Barton discusses this work with us in this linked podcast

www.buzzsprout.com/1794195/epis...

#IDSky #ClinMicro #yaws #Treponema #MDA #AMR #OpenAccess #OA

Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial A single oral dose of PanChol was safe and well tolerated at all doses and induced 100% vibriocidal seroconversion over a 100 000-fold dose range. These findings support the progression of PanChol int...

New Research:

Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial

www.thelancet.com/journals/lan...

Lassa viral dynamics: implications for missed diagnosis Lassa fever remains a significant public health problem in many west African countries. Attack rates, case positivity rates, and case fatality rates are often in the double digits in Sierra Leone, Lib...

New comment:

Lassa viral dynamics: implications for missed diagnosis

www.thelancet.com/journals/lan...

Lassa fever symptomatology, viral dynamics, and host immune response (PREPARE): a prospective, observational cohort study in Liberia In a region of Liberia where it is endemic, Lassa fever is a prevalent cause of morbidity and mortality. Several symptoms were more likely in those with Lassa fever but overlap with those caused by ot...

New Research:

Lassa fever symptomatology, viral dynamics, and host immune response (PREPARE): a prospective, observational cohort study in Liberia

www.thelancet.com/journals/lan...